Date:
Novo Nordisk A/S touted the potential of its next-generation obesity treatments, releasing promising data on an experimental daily pill and sending the shares soaring to a record.
A new treatment called amycretin, which targets two modes of action against obesity including GLP-1, like the blockbuster injection Wegovy, helped patients shed 13% of their weight over 12 weeks in an early-stage test. The early-stage results suggest the pill may be even more effective than Novo’s Wegovy injection.
NewsGala, a modern financial media outlet by Zeni Capital Corp. With 35 years of international finance expertise NewsGala strips away the distractions to provide timely and relevant financial news.
Our mission is to position our readers to have the best information to make profitable financial decisions and set realistic goals.
© 2021 Newsgala.com. All Rights Reserved.
